No Detail Found!

An Expert Opinion on Diabetic Care for Lower-Income Patient Groups in India: In Relation to the Availability and Afordability of Diabetic Medication

Author(s)
Sanjay Kalra Department of Endocrinology, Bharti Hospital,Karnal,India
Atul Dhingra Department of Endocrinology, Superspeciality Clinics and Gangaram Bansal Hospital, Sri Ganganagar, India
Mahesh DM Department of Endocrinology, Aster Corporate Hospital,Banglore,India
Manash Pratim Baruah Department of Endocrinology, Apollo Excelcare Hospital,Guwhati,India
Mangesh Tiwaskar Department of Endocrinology, Aster Corporate Hospital, Banglore, India
Navneet agrawal Department of Diabetology, Diabetes, Obesity and Thyroid Centre, Gwalior, India
Nilakshi Deka Department of Endocrinology, Apollo Hospitals,Guwhati,India
Pramila Kalra Department of Endocrinology, MSR Medical College, Banglore, India
Shailaja Kale Department of Diabetology, KEM Hospital,Pune,India
Santosh Revankar USV Private Limited, Mumbai, India
Abstract
The increasing burden of diabetes in India is imposing significant economic strain, particularly on lower socioeconomic groups. Therefore, the E-Tulip program aimed to improve healthcare outcomes for these patient groups with diabetes in India. Six nationwide continuing medical education sessions, each led by an expert healthcare professional (HCP) and attended by regional HCPs, focused on various aspects of 'Democracy in Diabetes Care'. Discussions from all the sessions were compiled to prepare this expert opinion. The recommendations provided tailored approaches for managing type 2 diabetes mellitus (T2DM) across diferent patient scenarios. Economic strategies emphasized afordability and adherence, advocating for metformin as a cost-efective first-line option and rationalizing dual (metformin + glipizide) and triple (glimepiride + metformin + pioglitazone) therapy choices based on glycemic control needs. Metformin was also endorsed for prediabetes to delay T2DM onset. The discussion on the availability and afordability of drugs will improve the knowledge of the HCPs, improving the care of lower-income diabetic patients through comprehensive management.
Publication Details
Page(s) 146-153
Published Journal: Liaquat National Journal of Primary Care, Volume: 7, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
type 2 diabetes mellitus, Metformin, Prediabetes, lower socioeconomic groups, expert opinion
References
Anjana RM,Unnikrishnan R,Deepa M,Pradeepa R,Tandon N,Das AK .2023 .Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMRINDIAB-17). Lancet Diabetes Endocrinol, 8587(23) : 00119-5.
Karachaliou F,Simatos G,Simatou A .2020 .The challenges in the development of diabetes prevention and care models in lowincome settings. Front Endocrinol (Lausanne), 11 : 518.
Unnikrishnan R,Anjana RM,Mohan V .2016 .Diabetes mellitus and its complications in India. Nat Rev Endocrinol, 12(6) : 357-70.
Oberoi S,Kansra P .2020 .Economic menace of diabetes in India: a systematic review. Int J Diabetes Dev Ctries, 40(4) : 464-75.
Kumpatla S,Kothandan H,Tharkar S,Viswanathan V. .2013 .The costs of treating long-term diabetic complications in a developing country: a study from India. J Assoc Physicians India, 61(2) : 102-9.
Polonsky WH,Henry RR .2016 .Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence, 10 : 1299-307.
Kalra S,Gupta Y,Sahay R. .2016 .The law of therapeutic parsimony. Indian J Endocrinol Metab, 20(3) : 180008-8210.
Samson SL,Vellanki P,Blonde L,Christofides EA,Galindo RJ,Hirsch IB .2023 .American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract, 02(5) : 305-40.
Diabetes Association Professional Practice American .2024 .Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 47(Suppl 1) : S158-78.
Kalra S,Bahendeka S,Sahay R,Ghosh S,Fariduddin Md,Orabi A .2018 .Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab, 556(1) : 17-57.
.2022 .pdf (cdsco. gov. Recommendations Endocrinology & Metabolism, 26 : 08.
.2022 .Standards of Care in Diabetes-2023 Abridged for Primary Care Providers. Clin Diabetes, 41(1) : 4-31.
.2022 .RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries, 42(Suppl 1) : 1-143.
.2016 .Cost-efective solutions for the prevention of type 2 diabetes. , : .
Swain SP,Samal S,Sahu KS,Rout SK .2018 .Out-of-pocket expenditure and drug adherence of patients with diabetes in Odisha. J Family Med Prim Care, 24(6) : 18-35.
Kirkman MS,Rowan-Martin MT,Levin R,Fonseca VA,Schmittdiel JA,Herman WH .2015 .Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care, 38(4) : 2098-9.
Aroda VR,Ratner RE .2018 .Metformin and type 2 diabetes prevention. Diabetes Spectr, 31(4) : 0020-42.
Mahabaleshwarkar R,A R .2020 .Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. Diabetes Res Clin Pract, 172 : 108531.
Vieira IH,Barros LM,Baptista CF,Rodrigues DM,Paiva IM .2022 .Recommendations for practical use of metformin, a central pharmacological therapy in type 2 diabetes. Clin Diabetes, 40(1) : 0043-107.
Young-Hyman D,de Groot M,Hill-Briggs F,Gonzalez JS,Hood K,Peyrot M. .2016 .Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care, 39(12) : 2053-40.
Tan HQM,Chin YH,Ng CH,Liow Y,Devi MK,Khoo CM .2020 .Multidisciplinary team approach to diabetes. An outlook on providers' and patients' perspectives. Prim Care Diabetes, 05(5) : 545-51.
Joyson BS,Jacob MS,Mathew F,Thomas J,Sushilkumar PL .2019 .Identification, assessment, and analysis of the cost-efectiveness of oral hypoglycemic agents for pharmacoeconomic evaluation in a tertiary care teaching hospital. World J Pharm Res, 8(12) : 1229-42.
Singh A,Dutta S,Varma A,Beg M,Kumar H,Kaur A .2016 .A drug utilization and pharmacoeconomic study of anti-diabetic drugs prescribed to type 2 diabetes mellitus patients visiting the medicine outpatient department of a tertiary care hospital of North India. Int J Basic Clin Pharmacol, 5(4) : 2319-2003.
Kodama N,Tahara N,Tahara A,Honda A,Nitta Y,Mizoguchi M .2013 .Efects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. J Clin Endocrinol Metab, 98(11) : 2920-45.
John M,Gopinath D,Kalra S. .2015 .Triple fixed drug combinations in type 2 diabetes. Indian J Endocrinol Metab, 19(3) : 152739-8210.
Banu S,Baburaj A,Johncy N,Chandur VK,Siva S. .2020 .A study on cost analysis in diabetic patients with cardiovascular complications in a tertiary care teaching hospital. Int J Health Sci Res, 10(April2020) : .
ElSayed NA,Aleppo G,Aroda VR,Bannuru RR,Brown FM,Bruemmer D .2023 .Cardiovascular disease and risk management: standards of medical care in diabetes-2023. Diabetes Care, 46(Suppl 1) : S158-90.
Arnett DK,Blumenthal RS,Albert MA,Buroker AB,Goldberger ZD,Hahn EJ .2019 .ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 140(11) : e596-646.
Papazafiropoulou AK,Melidonis A,Antonopoulos S. .2021 .Aspirin in primary prevention of cardiovascular disease in diabetes. Arch Med Sci Atheroscler Dis, 6 : e109-14.
Gillani SW,Syed Sulaiman SA,Menon V,Rahamathullah N,Elshafie RM,Rathore HA .2022 .6): e0270143. PLoS One, 17 : .
ElSayed NA,Aleppo G,Aroda VR,Bannuru RR,Brown FM,Bruemmer D .2023 .9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care, 46(Supplement) : S140-57.
Zhao JZ,Weinhandl ED .2020 .Glucose-lowering medication use in CKD: analysis of US medicare beneficiaries between 2007 and 2016. Kidney Med, 09(2) : 173-82.
Bailey CJ,Day C .2012 .Diabetes therapies in renal impairment. Br J Diabetes Vasc Dis, 12(4) : 167-71.
Yang G,Zeng G,Wu JP .2017 .Glipizide blocks renal interstitial ifbrosis by inhibiting AKT signaling pathway. Eur Rev Med Pharmacol Sci, 21(4) : 867-72.
Erdmann E,Dormandy J,Wilcox R,Massi-Benedetti M .2007 .PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag, 3(4) : 355-70.
Garber AJ,Handelsman Y,Grunberger G,Einhorn D,Abrahamson MJ,Barzilay JI .2020 .Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 Executive Summary. -0472, 26(1) : 107-39.
Alkhail BA,Iftikhar R,Shaikh AA .2016 .Use of Aspirin and Statin as primary prevention for cardiovascular diseases. Pak J Med Sci, 32(6) : 326-9.
Ho CC,Yang YS,Huang CN,Lo SC,Wang YH,Kornelius E. .2022 .2): e0264129. PLoS One, 17 : .
0

Citations

0

Downloads

37

Views